1492 Capital Management LLC Takes Position in Adaptive Biotechnologies Corporation $ADPT

1492 Capital Management LLC purchased a new position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 91,375 shares of the company’s stock, valued at approximately $1,484,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in shares of Adaptive Biotechnologies by 54.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,902,269 shares of the company’s stock worth $47,133,000 after acquiring an additional 1,022,417 shares during the last quarter. Rothschild Investment LLC increased its position in shares of Adaptive Biotechnologies by 29.3% during the 4th quarter. Rothschild Investment LLC now owns 13,293 shares of the company’s stock worth $216,000 after purchasing an additional 3,013 shares during the last quarter. Jupiter Asset Management Ltd. increased its position in shares of Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after acquiring an additional 91,683 shares during the last quarter. Intech Investment Management LLC increased its holdings in Adaptive Biotechnologies by 10.6% in the 4th quarter. Intech Investment Management LLC now owns 64,391 shares of the company’s stock valued at $1,046,000 after purchasing an additional 6,155 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after buying an additional 110,825 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Trading Up 5.6%

Shares of ADPT stock opened at $15.99 on Thursday. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -48.45 and a beta of 2.15. The stock has a 50 day simple moving average of $14.03 and a 200-day simple moving average of $15.57. Adaptive Biotechnologies Corporation has a 12-month low of $9.78 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.20) EPS. On average, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ADPT has been the topic of a number of recent research reports. Guggenheim reiterated a “buy” rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. TD Cowen upped their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, BTIG Research reaffirmed a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Insider Transactions at Adaptive Biotechnologies

In related news, insider Harlan S. Robins sold 470,266 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the transaction, the insider directly owned 1,522,058 shares of the company’s stock, valued at $20,045,503.86. This trade represents a 23.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sharon Benzeno sold 63,103 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $831,066.51. Following the completion of the transaction, the insider directly owned 272,751 shares of the company’s stock, valued at $3,592,130.67. The trade was a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,771,096 shares of company stock worth $23,926,217 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.